Dissemin is shutting down on January 1st, 2025

Published in

European Centre for Disease Prevention and Control, Eurosurveillance, 26(13), 2008

DOI: 10.2807/ese.13.26.18914-en

Links

Tools

Export citation

Search in Google Scholar

Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype

Journal article published in 2008 by P. Kaaijk ORCID, Ba A. van der Zeijst, Van Der Zeijst, Mc C. Boog, Cw W. Hoitink
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

As reported in a recent issue of Eurosurveillance, a mumps outbreak is ongoing in the Netherlands despite high vaccination coverage of 90-95% [1]. The reported mumps cases are restricted to geographic regions with a high percentage of residents who are members of a religious community that rejects vaccination. Consequently, two thirds of the mumps patients were not vaccinated. However, also vaccinated individuals in these regions were affected [1]. Since 1987, the measles-mumps-rubella (MMR) combination vaccine produced by the Netherlands Vaccine Institute (NVI) is part of the Dutch national immunisation programme and administered at the ages of 14 months and nine years.